Skip to main content

Table 1 The baseline characteristics of the NSCLC patients with and without prior cancer

From: Is prior cancer history a hindrance for non-small cell lung cancer patients to participate in clinical trials?

Characteristics

with prior cancer (N = 338)

without prior cancer (N = 3,764)

P

Age, years

  

 < 0.001a

 Median (range)

60 (29–84)

61 (18–86)

 

Sex

  

 < 0.001

 Male

112 (33.1)

1,957 (52.0)

 

 Female

226 (66.9)

1,807 (48.0)

 

Smoking

  

 < 0.001

 Non-smoker

252 (74.6)

2,410 (64.0)

 

 Smoker

86 (25.4)

1,354 (36.0)

 

Family tumor history

  

0.023

 Without

289 (85.5)

3,369 (89.5)

 

 With

49 (14.5)

395 (10.5)

 

Preoperative comorbidity

  

0.120

 Without

127 (37.6)

1,578 (41.9)

 

 With

211 (62.4)

2,186 (58.1)

 

BMI

  

0.094a

 Median (range)

24.1 (15.6–38.9)

24.0 (14.3–44.8)

 

FEV1 (%)

  

0.470a

 Median (range)

95.9 (21.1–259.0)

94.2 (52.6–165.0)

 

DLCO (%)

  

0.003a

 Median (range)

87.5 (11.6–160.8)

83.7 (41.5–708.0)

 

Clinical T category

  

0.007

 1

285 (84.3)

2,910 (77.3)

 

 2

44 (13.0)

589 (15.6)

 

 3

6 (1.8)

173 (4.6)

 

 4

3 (0.9)

92 (2.4)

 

Clinical N category

  

0.048

 0

309 (91.4)

3,268 (86.8)

 

 1

3 (0.9)

69 (1.8)

 

 2

26 (7.7)

427 (11.3)

 

ASA grade

  

 < 0.001b

 1

36 (10.7)

758 (20.1)

 

 2

291 (86.1)

2,840 (75.5)

 

 3

11 (3.3)

162 (4.3)

 

 4

0 (0.0)

4 (0.1)

 

Surgical approach

  

0.005

 VATS

315 (93.2)

3,317 (88.1)

 

 Open

23 (6.8)

447 (11.9)

 

Surgical extent

  

0.011

 Lobectomy

230 (68.0)

2,769 (73.6)

 

 Sublobectomy

104 (30.8)

904 (24.0)

 

 Pneumonectomy

4 (1.2)

91 (2.4)

 

Tumor location

  

0.521

 Right upper lobe

119 (35.2)

1,193 (31.7)

 

 Right middle lobe

18 (5.3)

241 (6.4)

 

 Right lower lobe

61 (18.0)

784 (20.8)

 

 Left upper lobe

92 (27.2)

981 (26.1)

 

 Left lower lobe

48 (14.2)

565 (15.0)

 

Histology

  

0.364

 ADC

282 (83.4)

3,020 (80.2)

 

 SCC

45 (13.3)

596 (15.8)

 

 Other

11 (3.3)

148 (3.9)

 

VPI

  

0.310

 Without

271 (80.2)

2,928 (77.8)

 

 With

67 (19.8)

836 (22.2)

 

LVI

  

0.062

 Without

299 (88.5)

3,187 (84.7)

 

 With

39 (11.5)

577 (15.3)

 

Tumor size, cm

  

0.005

 Continue

1.8 (0.1–14.0)

1.5 (0.4–13.0)

 

Pathologic T category

  

0.006

 1

228 (67.5)

2,235 (59.4)

 

 2

93 (27.5)

1,165 (31.0)

 

 3

10 (3.0)

255 (6.8)

 

 4

7 (2.1)

109 (2.9)

 

Pathologic N category

  

0.138

 0

284 (84.0)

2,992 (79.5)

 

 1

21 (6.2)

302 (8.0)

 

 2

33 (9.8)

470 (12.5)

 

Pathologic TNM stage

  

0.004

 I

269 (79.6))

2,697 (71.7)

 

 II

26 (7.7)

486 (12.9)

 

 III

43 (12.7)

581 (15.4)

 

Postoperative complications

  

0.142

 Without

317 (93.8)

3,596 (95.5)

 

 With

21 (6.2)

168 (4.5)

 

Adjuvant therapy

  

0.003

 No

270 (79.9)

2,721 (72.3)

 

 Yes

68 (20.1)

1,043 (27.7)

 

Hospital stay, day

  

0.668a

 Continue

12 (2–61)

12 (2–99)

 
  1. NSCLC non-small cell lung cancer, BMI body mass index, FEV1 forced expiratory volume in 1 s, DLCO diffusion capacity for carbon monoxide, TNM tumor-node-metastasis, ASA the American Society of Anesthesiologists, VATS video assisted thoracic surgery, ADC adenocarcinoma, SCC squamous cell carcinoma, VPI visceral pleural invasion, LVI lymphovascular invasion
  2. a Mann–Whitney U test
  3. b Fisher’s exact test